The Proven GLP-1 for Weight Loss
Wegovy® (Semaglutide)Wegovy® (semaglutide) is FDA-approved for chronic weight management—the same medication as Ozempic at higher doses optimized specifically for weight loss.
Avg weight loss
15-17%
vs retail
87%
up to 87% savings
Frequency
Once Weekly
GLP-1 medications are priced separately: Ozempic starts at $175/month and Zepbound starts at $275/month, up to 75% less than retail pharmacy prices.
How Wegovy works
Wegovy mimics the GLP-1 hormone your body naturally produces after eating. It works on the brain to reduce appetite and increase feelings of fullness, while also slowing stomach emptying. This creates a powerful combination that helps you eat less without feeling deprived.
Clinical evidence
In the STEP trials, patients taking Wegovy lost an average of 15-17% of their body weight over 68 weeks—roughly 35 pounds for the average participant.
Benefits at PWL
- FDA-approved specifically for weight loss
- Proven 15-17% average body weight reduction
- Established safety profile with years of data
- Once-weekly convenient injection
- Significant appetite and craving reduction
- Cardiovascular benefits (reduced heart attack/stroke risk)
- Improvement in blood pressure and cholesterol
- Well-studied with extensive clinical trial data
Common side effects
- Nausea (usually improves by week 4-8)
- Diarrhea or vomiting
- Constipation
- Abdominal pain
- Headache or fatigue
Side effects are typically mild and improve over time. Your provider guides you on managing any symptoms during your monthly check-ins.
Who Should Not Take Wegovy
- ⚠Personal history of pancreatitis
- ⚠Personal or family history of medullary thyroid cancer (MTC)
- ⚠Personal or family history of multiple endocrine neoplasia type 2 (MEN2)
- ⚠Pregnant or breastfeeding patients
- ⚠Patients with severe gastrointestinal motility disorders, with case-by-case provider review
Black Box Warning
Semaglutide causes thyroid C-cell tumors in rodents. It is not known whether Wegovy causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Wegovy is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should be counseled regarding the potential risk of MTC and symptoms of thyroid tumors.
Medically reviewed by Dr. Scott Friedman, MD ·
Common Questions About Wegovy
How much weight can I lose with Wegovy?
Clinical trials (STEP for Wegovy, SUSTAIN for Ozempic) showed average weight loss of 15-17% with semaglutide. For someone starting at 250 lbs, that is approximately 37-42 pounds. Individual results vary based on starting weight, adherence, dose, and lifestyle factors.
What are the most common Wegovy side effects?
Nausea, mild GI changes, constipation, fatigue, and occasional acid reflux are most common, especially during the first few weeks and after dose increases. Most side effects are mild and resolve with dose adjustment, hydration, increased fiber and protein, and time. Your provider monitors closely throughout treatment.
Is Wegovy brand-name or compounded?
Premier Weight Loss prescribes only brand-name, FDA-approved Wegovy. We never use compounded alternatives. All medication arrives in original manufacturer packaging.
How much does Wegovy cost at Premier Weight Loss?
Wegovy starts at $175/month at Premier Weight Loss, up to 75% less than retail pharmacy prices. Final pricing depends on dose and is confirmed with your provider during the consultation. Available via virtual care, shipped to your Indiana address.
How is Wegovy different from the other GLP-1s you prescribe?
Wegovy (semaglutide) acts on the GLP-1 receptor alone. Tirzepatide (Mounjaro, Zepbound) is dual-action (GIP + GLP-1) and typically shows higher weight loss in trials. Your provider will recommend the best option based on your goals, health profile, and treatment response.
Other Medications We Prescribe
Ready to start with Wegovy?
Reserve a $45 consult. Your provider will confirm the right medication and dose for you.